Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Diagnostic Approach and Treatment for Valley Fever

Diagnostic Testing

  • The primary diagnostic method for valley fever involves serologic testing, with antifungal treatment recommended only for severe disease or high-risk patients, according to the Infectious Diseases Society of America 1
  • Testing should include both IgM and IgG antibodies against coccidioidal antigens, as recommended by the Infectious Diseases Society of America 1
  • For patients with suspected exposure, comparative testing of acute and convalescent serum samples (6 weeks apart) is recommended to detect seroconversion, as suggested by the Infectious Diseases Society of America 1
  • Nucleic acid detection via PCR can be useful in early disease (first 2 weeks) before antibody response develops, according to the Centers for Disease Control and Prevention 3

Treatment Recommendations

  • For immunocompetent patients with mild to moderate symptoms, antifungal therapy is generally not required as most infections are self-limited, according to the Infectious Diseases Society of America 4
  • Patient education about disease course and when to seek further medical attention is essential, as recommended by the Infectious Diseases Society of America 4
  • Severe primary pulmonary disease with significant symptoms requires antifungal therapy, according to the Infectious Diseases Society of America 4
  • Fluconazole is the first-line treatment, with 400 mg daily for mild-moderate disease and 800 mg daily for severe disease, as recommended by the Infectious Diseases Society of America 4
  • Itraconazole (200 mg twice daily) may be more effective for skeletal infections, according to the Infectious Diseases Society of America 4
  • Liposomal amphotericin B is recommended for critically ill patients, rapidly progressive disease, and patients who fail to respond to azole therapy, as suggested by the Infectious Diseases Society of America 4
  • Avoid unnecessary antifungal treatment in immunocompetent patients with mild disease, as this can lead to adverse effects without clinical benefit, according to the Infectious Diseases Society of America 4
  • Treatment should never be delayed while awaiting laboratory confirmation if clinical suspicion is high in high-risk patients, as recommended by the Infectious Diseases Society of America 4
  • Surgical intervention should be considered for persistent symptomatic cavities present for more than 2 years, according to the Infectious Diseases Society of America 4